Drug intelligence / Profile preview

ΣΦ-4001

Development stage: Preclinical
Lead developer: Sigmapharm Laboratories

Overview

ΣΦ-4001 is an internal development code used by Sigmapharm Laboratories for a product within its pipeline of unique generic and branded products. As of late 2018, the asset was listed as being prepared for either an Abbreviated New Drug Application (ANDA) or a New Drug Application (NDA) submission. Sigmapharm characterizes this product as having 'Barrier-to-Entry Properties,' which could involve complex formulation, patent litigation, bioavailability, or stability challenges. The specific chemical identity, therapeutic indication, and mechanism of action remain undisclosed by the developer.

Beyond the preview

Go deeper on ΣΦ-4001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ΣΦ-4001.

Explore the full profile